Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2 clinical trials
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

epidermal growth factor
international normalized ratio
oophorectomy
palbociclib
toremifene
  • 0 views
  • 19 Feb, 2024
Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer

This single arm pilot study evaluates the use of neoadjuvant endocrine therapy in women with early stage ER+ breast cancer who are 70 years or older and are scheduled to have breast conservation surgery (BCS). The purpose of this study is to see if tolerance of neoadjuvant endocrine therapy helps …

estrogen receptor positive breast cancer
tamoxifen
adjuvant
breast cancer
aromatase inhibitor
  • 0 views
  • 19 Feb, 2024